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Abstract
We identified a discrete number of microRNAs differentially expressed in benign or malignant 
mesothelial tissues. We focused on mir-145 whose levels were significantly downregulated in 
malignant mesothelial tissues and Malignant pleural mesothelioma (MPM) cell lines as compared 
to benign tissues (pleura, peritoneum or cysts). We show that promoter hyper-methylation caused 
very low levels in MPM cell lines. Treatment of MPM cell lines with mir-145 agonists negatively 
modulated some protumorigenic properties of MPM cells, such as clonogenicity, cell migration 
and resistance to pemetrexed treatment. The main effector mechanism of the clonogenic death 
induced by mir-145 was that of accelerated senescence. We found that mir-145 targeted OCT4 via 
specific binding to its 3’-UTR. Increased intracellular levels of mir-145 decreased the levels of 
OCT4 and its target gene ZEB1 thereby counteracting the increase of OCT4 induced by 
pemetrexed treatment which is known to favor the development of chemoresistant cells. In line 
with this, reintroduction of OCT4 into mimic-145 treated cells counteracted the effects on 
clonogenicity and replicative senescence. This further supports the relevance of the mir-145-
OCT4 interaction for the survival of MPM cells. The potential use of mir-145 expression levels to 
classify benign vs malignant mesothelial tissues and the differences between pemetrexed-induced 
senescence and that induced by the re-expression of mir-145 are discussed.
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INTRODUCTION
Malignant pleural mesothelioma (MPM) is a tumor originating from the mesothelial surfaces 
of the lung and characterized by an overall bad prognosis(1). Chronic inflammation 
(consequent to asbestos exposure) and genetic predisposition are major players in MPM 
pathogenesis (2). Additionally, because of the use of asbestos in the ‘70s, the incidence of 
MPM is expected to peak in the next few years (2). Two main features influence the 
prognosis of MPM: first, its silent clinical progression, which leads to very late diagnosis 
and thus strongly limits therapeutic intervention (i.e surgical resection). Second, its extreme 
resistance to current chemotherapeutic agents which dramatically hampers the disease-free-
survival of the treated patients (3, 4). Therefore, identification of diagnostic biomarkers for 
MPM would be relevant for early diagnosis and patient stratification, in addition to 
contributing to our understanding of the basic mechanisms of MPM progression.
MicroRNAs (miRs) are short (17–22 nucleotides) noncoding RNAs that regulate gene 
expression by inhibiting protein translation, through base-pairing mediated interaction with 
the 3’UTR of target mRNAs(5, 6). Given their ability to simultaneously target multiple 
genes/pathways, transient or stable modulation of intracellular microRNA levels is a 
powerful way to transduce adaptive stimuli leading to broad changes in pathway activation. 
Growing evidence suggest that microRNAs play a major role in oncogenesis, with either 
tumor suppressor or tumor-promoting modalities(7–9). MicroRNAs are much more stable 
than mRNAs and this phenomenon allows an assessment of their expression levels 
retrospectively from frozen or fixed tissues. This feature, together with their rather tissue-
specific expression, has prompted the study of microRNAs expression levels as an important 
diagnostic and prognostic tool for a number of solid and non-solid malignancies (9). 
Additionally, the study of cancer-associated microRNAs may prove useful in order to 
elucidate the mechanism(s) behind cell transformation. For example, the identification of 
low levels of mir-29c* in MPM has provided both a prognostic tool for epithelial MPM and 
has pointed to aberrant chromatin methylation for the progression of MPM(10). Here we 
investigated whether specific microRNAs could distinguish malignant mesotheliomas from 
benign mesothelial lesions (mesothelial cysts, normal pleura and peritoneum). This allowed 
us to identify a discrete group of microRNAs possibly endowed with diagnostic potential. 
Among the identified candidates, we further characterized the microRNA-145 (mir-145), 
whose expression was very low in MPM tissues and cell lines, as compared to benign 
mesothelial tissues or untransformed mesothelial cells. Mir-145 may represent a potential 
tumor suppressor, since its expression has been found downregulated in a number of solid 
tumors, including prostate and bladder tumors, endometrial adenocarcinomas and gliomas 
(11–14). The homeodomain-containing transcription factor OCT4 is among the multiple 
targets of mir-145 (13, 15). The OCT4 gene (also named POU5F1) plays an important role 
in activating self-renewal gene programs in embryonic tissues and stem cells(16). OCT4 is 
found overexpressed in poorly differentiated and high-grade tumors, with potential to 
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support aberrant proliferation, tumor initiation and chemoresistance (17–21). These 
properties have been shown to reside in its ability to control Epithelial to Mesenchymal 
transition (EMT)(22) as shown in mouse models of metastatic colon cancer (23). In fact, 
RNAi-based downregulation of OCT4 in vitro affects growth and tumorigenicity of ovarian 
cancer cell lines (24). We found here that mir-145 has the potential to modulate many in 
vitro pro-tumorigenic features of MPM cells, including growth, clonogenicity and resistance 
to pemetrexed treatment. Additionally, transfection of mimic-145 into MSTO-211H cells 
strongly reduced tumor engraftment in vivo. Induction of replicative senescence accounted 
for the clonogenic death induced by the treatment of MPM cells with mir-145 agonists. 
Mir-145 directly targeted OCT4 and, indirectly, its EMT-promoting target ZEB1 in MPM 
cells and the levels of mir-145 and OCT4 inversely correlated in vivo. OCT4 targeting is 
crucial to the anticancer properties of mir-145. In fact, mimic-145 expression counteracted 
the increase of OCT4 in pemetrexed resistant MPM cells. Additionally, overexpression of 
OCT4 at least partially rescued the effects of mimic-145 on the clonogenicity and replicative 
senescence of the targeted MPM cells. Promoter hyper-methylation may contribute the low 
levels of mir-145 in MPM cells and malignant MPM tissues. In summary, in this work, we 
have identified mir-145 downregulation as a characteristic trait of malignant vs benign 
mesothelial tissues. Additionally, we provide insights into the possible contribution of 
mir-145-OCT4 interaction to the transformed phenotype of MPM cells.
RESULTS
Identification of microRNAs differentially expressed among malignant and benign 
mesothelial tissues (Fig.1)
We performed an unbiased microRNA screening of MPM specimens (n= 29) and 
mesothelial benign tissues (mesothelial cysts, n=12). In Table I the main histoclinical 
features of cysts and MPMs are reported. As expected by the reported incidence distribution 
of mesothelioma subtypes in Western populations (25) more than 80% of cases were 
represented by the epithelioid mesothelioma (Table 1). All the analyzed specimens derived 
from surgically resected, naïve –treated patients. Our analysis revealed striking differences 
in the microRNA expression profile of benign vs malignant mesothelial tissues and allowed 
us to identify a discrete number of microRNAs (n=19) which showed statistically significant 
opposite modulation in benign vs malignant tissues (Fig. 1A, heat map). PCA analysis 
confirmed the ability of the 19 selected microRNAs to discriminate between the benign and 
malignant tissues. This was particularly evident on the first component, accounting for 
42.24% of the total variance (Fig. 1B). Among the differentially expressed microRNAs, a 
larger fraction showed higher levels in benign lesions (n= 13) while a restricted number 
showed strong downregulation in the malignant tissues (n=6)(Fig. 1A). We focused on 
microRNA-145 (mir-145), because it showed the highest intensity values in its subgroup and 
because its modulation in our samples suggested the potential to act as a tumor suppressor. 
Additionally, mir-145 has been recently shown to modulate EMT, a key feature of MPM(26, 
27).
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Mir-145 is downregulated in MPM specimens and MPM cell lines but not in untransformed 
mesothelial cells (Fig.1)
We validated the previous results in two ways. Firstly, we assessed the levels of mir-145 by 
quantitative PCR on unmatched MPM and pleural biopsies obtained from patients (n=20, of 
which 6 MPM and 14 benign tissue) not belonging to the first set analyzed (Fig. 1C). As 
shown by the box plot (Fig 1C), we found that mir-145 expression was significantly 
downregulated in this validation group, thus confirming our initial findings. Secondly, we 
assessed the mir-145 levels in snap-frozen matched pair samples (n=36) of peritoneal 
mesothelium vs MPM (Fig. 1D). This, again, revealed that mir-145 levels were significantly 
lower in the matched tissues (p<0.001)(Fig. 1D). In summary, our analysis revealed a 
statistically significant downregulation of mir-145 levels in MPM as opposed to the benign 
tissues, irrespectively whether the latter was derived from cysts, normal mesothelium or 
peritoneal mesothelium from the same patient (Fig. 1). Mir-145 downregulation was 
observed in both paraffin-embedded MPM material and from snap-frozen sections. 
Additionally, the analyzed specimens were derived from three independent institutions (see 
discussion), thus strengthening further our results. To facilitate a functional characterization 
of mir-145 in MPM, we tested whether mir-145 downregulation was conserved in 
representative MPM cell lines as well (Fig. 1E). Quantitative PCR (Q-PCR) analysis showed 
that mir-145 expression was deeply downregulated in three MPM cell lines (MSTO-211H, 
NCI-H2052 and NCI-H28) when compared to untransformed mesothelial cells (HMC) (Fig. 
1E). Of note, the MPM cell lines were different both in histologic type (epithelioid, 
sarcomatoid, byphasic) and growth properties (ATCC.org). This suggests that mir-145 
downregulation is independent of MPM type and that our in vitro system could recapitulate 
what observed in the initial microRNA screening of the patient samples (Fig. 1 and table 1). 
Therefore, we decided to use the mentioned MPM cell lines to characterize the effect of 
mir-145 downregulation on MPM cells.
Re-expression of mir-145 affects viability and clonogenicity and migration of the MPM cell 
lines (Fig.2)
The broad downregulation of mir-145 in the malignant mesothelial tissues (as compared to 
the benign ones) suggested that mir-145 might act as a tumor suppressor. Therefore, we 
hypothesized that increased levels of mir-145 could counteract some of the malignant 
features of the MPM cell lines. To this aim, we transfected control- or mir-145 molecules in 
MSTO-211H, NCI-H2052 and NCI-H28 MPM cell lines (Fig.2). Transfection of the 
mir-145 agonist significantly affected the time dependent growth of all three tested MPM 
cell lines (p<0.05)(Fig. 2A left panel). To detail the observed effect on cell growth, we 
performed clonogenic assays from the same MPM cell lines (Fig. 2A middle and right 
panels). The clonogenic assay is useful to assess the long-term in vitro tumorigenic capacity 
of transformed cells in a way independent of acute toxic effects due to liposome 
transfection. This revealed a strong inhibition of colony forming ability in the cell lines 
transfected with mir-145, as compared to control-transfected cells (Fig. 2A middle and right 
panels, p<0.05).
Finally, we evaluated the effect of mir-145 transfection on the migratory properties of MPM 
cells. Transwell cell migration assays revealed that the migration of NCI-H2052 and 
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MSTO-211H transfected with mir-145 was strongly reduced, as compared to control-
transfected counterparts (Fig 2B, left and right panels, p<0.05). Inhibition of cell migration 
was also observed by scratch assays as well at early time points (Suppl. Fig. 1, left and right 
panel). We could not test the NCI-H28 cell line in this experimental context, since the latter 
cells did not show significant migratory properties at steady state (unpublished 
observations). Altogether, these observations revealed that forced expression of mir-145 in 
transformed mesothelial cells affects three protumorigenic features, namely cell growth, 
clonogenicity and cell migration. Further, to evaluate if the observed effects of mir-145 re-
expression would translate in anticancer effects in vivo, we performed xenograft 
experiments. SCID mice were subcutaneously transplanted with MSTO-211H cells 
transfected with either ctrl- or mimic-145 16hrs before injection (fig. 2C). No differences in 
cell viability were observed in the two groups of injected cells at time of injection. We 
observed a significant inhibition of tumor growth in the mice engrafted with mimic-145 
transfected cells. In fact, we observed tumor formation (cut off: volume >150mm3) in 8/8 
mice injected with ctrl- transfected cells and in 2/8 mice injected with mimic-45 transfected 
cells (p<0.05) (fig. 2C). Additionally, the tumors grown from mimic-145 transfected 
MSTO-211H were significantly smaller than those grown from their control-transfected 
counterparts (p<0.05) (Fig.2C).
Mir-145 expression triggers senescence of MPM cells (Fig. 3)
A closer look at the colonies formed by control- and mimic-145 transfected cells as from 
Fig. 2A, revealed that the in the mimic-145 expressing cells the colonies were composed of 
bigger, flat cells and showed reduced cell density, reminiscent of a senescent cell phenotype. 
Therefore, we investigated whether re-expression of the mir-145 in transformed MPM cell 
lines could trigger senescence. SA-β–galactosidase staining (at pH 6) of both MSTO-211H 
and NCI-H2052 cells transfected with ctrl or mimic-145 revealed strong staining in most of 
the cells expressing mimic-145, with no or little staining observed in the control cells at 5 
days after transfection (Fig. 3A upper and lower panel p<0.05). To provide further evidence 
for the induction of replicative senescence by mir-145 overexpression, we evaluated by 
Western Blotting the levels of lamin B1, acetylated Histone H3 (AcH3K9) and p21 protein 
in ctrl- and mimic-145 treated MSTO-211H and NCI-H2052 cells. This revealed a 
significant reduction of both lamin B1 and AcH3K9 and induction of the p21 proteins in 
both mesothelioma cell lines transfected with mimic-145 (as compared to ctrl-transfected 
cells)(Fig. 3B). Lastly, we observed increased formation of senescence-associated 
heterochromatin foci (SAHF) in the mimic-145 transfected cells (Fig. 3C). SAHF are 
specialized domains of facultative heterochromatin, known contribute to senescence-
associated cell growth arrest by sequestering and silencing proliferation-promoting genes. 
All the observed changes are strongly suggestive of replicative senescence (28–33). 
Altogether, these observations support the idea that mir-145 expression induces senescence 
in MPM cells and that induction of replicative senescence may mediate the anti-clonogenic 
effects of mimic-145 transfection.
Mir-145 targets OCT4 in MPM cells (Fig. 4)
The observed biological effects of mir-145 expression on MPM cell lines prompted us to 
investigate which gene products could mediate its effects. Literature mining and in silico 
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analysis with multiple target finding algorithms revealed several targets of mir-145 with 
relevance for cancer development (unpublished observations). We focused on OCT4 
because of its involvement in modulating aggressive features of solid tumors (19, 20, 23). 
We and others have previously shown that increased OCT4 levels correlate with the 
resistance of mesothelioma cells to pemetrexed in vitro (34, 35). In addition, the acquisition 
of an hypermigratory phenotype is a main feature of transformed cells and requires the 
reactivation of pathways governing the epithelial to mesenchymal transition (EMT)(36). 
Initially, we confirmed targeting of the OCT4 3’UTR region by mir-145 by assessing the 
luciferase activity of HEK293 cells co-transfected with a double luciferase reporter (whose 
activity was driven by the OCT4 3’ UTR) and a mir-145 expression vector (Fig. 3A). This 
revealed that transfection of the mir-145 significantly affected the translation of the 
luciferase mRNA in the targeted cells, as shown by a drop of the enzyme activity (Fig 3A). 
Additionally, such effect was specific for mir-145, since it was abolished in cells transfected 
with a mutant 3’UTR construct unable to bind to mir-145 (Fig 3A). Next, we analyzed by 
western blotting the protein levels of OCT4 in control-vs mimic-145 transfected 
MST0-211H and NCI-H2052 cells. Our analysis revealed that mir-145 overexpression 
affected the protein levels of OCT4 (Fig. 3B upper panels). We also tested the effect of 
mimic-145 on exogenously expressed OCT4 in both MPM cell lines, by transfecting an 
OCT4 expression vector harboring a wt 3’UTR (37) in mimic-145 treated cells. This 
confirmed a specific decrease of the exogenously expressed OCT4 protein in the mimic-145 
transfected cells (Fig.3B lower panels). Further, we confirmed the downregulation of OCT4 
by staining MSTO-211H (and NCI-H2052) cells co-transfected with GFP and mimic-145 
with anti-OCT4 antibodies (Fig.3 C). This in fact showed a significant drop of OCT4 
staining in the (GFP-positive) mimic-145 transfected cells (Fig. 3C, p<0.05). 
Downregulation of OCT4 per se is compatible with the biological effects of mimic-145 we 
observed in vitro, with regard to the inhibition of cell growth, migration and clonogenicity 
(Fig. 2) In fact OCT4 has been recently shown to control the expression of pivotal EMT 
promoting genes, including ZEB1, whose expression is relevant for MPM progression (26). 
Western blotting analysis of lysates derived from control- and mimic-145 transfected cells 
revealed in fact significantly lower levels of ZEB1 protein in both mimic-145 treated 
MSTO-211H and NCI-H2052 cells (Suppl. Fig. 2). Lastly, we performed FACS staining of 
ctrl- and mimic-145 transfected MSTO-211H and NCI-H2052 cells (Fig. 4D). This revealed 
that mimic-145 transfection strongly reduced the number of OCT4-positive cells (8.94% ± 
2.2 vs 1.94 ± 0.8% for ctrl- and mimic-145 transfected cells, respectively) (Fig. 4D, upper 
and lower panel), therefore mirroring the previous results. In summary, mimic-145 treatment 
of MPM cell lines affected the levels of endogenous OCT4 as well as the levels of the 
exogenously expressed protein.
Mir-145 and OCT4 expression levels inversely correlate in vivo (Fig. 4E)
Since the forced expression of mir-145 triggers OCT4 downregulation, we predict that lower 
mir-145 levels may correlate with increased expression of OCT4 in vivo. To verify this, we 
performed immunohistochemistry staining for OCT4 of paraffin embedded sections derived 
from the same samples used for our initial microRNA screening (Fig. 1A), for which the 
levels for mir-145 were previously determined (Fig 1A). This showed that, as compared to 
the reference benign tissues (cysts), the levels of OCT4 were higher in all the MPM samples 
Cioce et al. Page 6
Oncogene. Author manuscript; available in PMC 2015 December 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
ranging from 21–89% positive cells vs 18% in the cyst (Fig. 4-E.). Additionally we found a 
significant correlation between the extent of mir-145 downregulation and the number of 
OCT4 positive cells (Fig. 4E-linear regression analysis: r: 0.77; r2: 0.59; p value <0.01), 
thus enforcing the relevance of mir-145 targeting of OCT4.
OCT4 antagonizes the miR-145 -mediated suppression of MPM protumorigenic features 
(Fig.5)
To correlate the anti-cancer effects of mimic-145 with its activity toward the OCT4 gene 
product, we hypothesized that mimic-145 may antagonize the increase of OCT4 induced by 
pemetrexed treatment. In fact, we and others have shown that emergence of chemoresistant 
clones within pemetrexed and cisplatin-treated MPM cell lines is linked to the upregulation 
of EMT and stemness-related genes, including OCT4 (34, 35). Therefore, we evaluated the 
ability of mimic-145 to affect the levels of OCT4 in pemetrexed treated cells. FACS staining 
of ctrl- and mimic-145 transfected MSTO-211H cells treated with pemetrexed revealed in 
fact a significant increase of the number of OCT4 positive cells in the ctrl-transfected ones 
(Fig. 5A, left panel) (as compared to vehicle treated cells-fig. 4B). This effect was strongly 
reduced in their mimic-145 transfected counterparts (Fig. 5A, right panel) (24.94 ± 2.3 vs 
6.22 ±1.1%, respectively).Similar results were obtained when using NCI-H2052 cells (data 
not shown). Additionally, we performed western blotting analysis with anti-OCT4 
antibodies of lysates derived from the same cells as in fig. 5A: this revealed a significant 
decrease of OCT4 induction in MSTO-211H cells transfected with mimic-145 and treated 
with pemetrexed as compared to the similarly treated, ctrl-transfected cells(Fig. 5B). Based 
on these results, we predicted that overexpression of OCT4 could counteract the tumor-
suppressive properties of the mimic-145. To this aim, we transfected control – or mimic-145 
treated MSTO-211H and NCI-H2052 cells with an OCT4 expressing vector (or with an 
empty vector) and we evaluated the properties of the transfected cells (Fig.5B–C). We found 
that exogenous expression of OCT4 (and not that of the empty vector-EV) significantly 
attenuated the effect of mimic-145 on the clonogenicity of the transfected cells. In fact, 
mimic-145 +OCT4 transfected cells formed significantly more colonies than their control 
counterparts (Fig. 5C, p<0.05). Further, we evaluated the effect of OCT4 overexpression on 
the extent of cell senescence induced by the expression of mimic-145 (Fig. 5D). This 
revealed a significant reduction of the number of SA-β-Galactosidase positive cells in the 
OCT4 + mir-145 expressing cells as opposed to the EV+mir-145 transfected cells (Fig. 5D, 
p<0.05). In summary, these observations further strengthen the physical and functional 
relevance of the mir-145-OCT4 interaction. Our observations are also reminiscent of 
previous work showing the potential for OCT4 overexpression to bypass the senescence of 
human primary breast cells (38).
Promoter methylation may contribute to mir-145 silencing in MPM cell lines (Fig. 6)
We have found the levels of mir-145 downregulated in neoplastic mesothelial tissues and 
MPM cell lines, as opposed to benign tissues and untransformed mesothelial cells, 
respectively. We next investigated how the levels of mir-145 could be downregulated in 
tumor samples. Therefore we investigated the methylation status of all the DNA CpG 
islands represented within the regulatory regions of the mir-145 promoter (Fig. 6A). We 
performed pyrosequencing assays on normal and malignant mesothelial tissues, respectively 
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(Fig. 6B, upper and lower panels). This showed a general decrease of DNA methylation in 
all CpG islands analyzed (within the mir-145 promoter), in the mesothelia as compared to 
the mesothelioma tissues (average methylation: 46% ± 7% vs 83% ± 3%, for mesothelium 
vs mesothelioma, respectively, p<0.01) (Fig. 6C). The difference in methylation was even 
more evident for the CpG islands located closer to the transcription start site (Fig. 6B upper 
and lower panels). Further, we analyzed the methylation of the same CpG islands in 
MSTO-211H and NCI-H2052 cells treated with either vehicle or 5-Azacytidine (5-
AZA-10uM, 96hrs), a DNA demethylating agent currently tested in clinical trials for 
myelodisplastic syndromes (MDS)25. 5’AZA treatment is expected to counteract the 
transcriptional repression due to promoter DNA hyper-methylation. This revealed a dramatic 
change in the methylation status of the CpG islands in the cells treated with 5’AZA (Suppl. 
Fig.3A and 3B) which readily matched the increase of mir-145 levels as assessed by 
semiquantitative PCR (Suppl. Fig. 3C). These observations support the idea that increased 
DNA methylation may be responsible for the low levels of mir-145 in both mesotheliomas 
and mesothelioma cell lines.
DISCUSSION
We investigated whether specific microRNAs could distinguish a large group of 
mesotheliomas from benign mesothelial lesions cysts, pleura or peritoneum. To reduce a 
possible “single-institution bias” in the sample collection, the specimens used for both the 
screening and the validation have been independently derived from different institutions, all 
reference centers for mesothelioma therapy, and analyzed with two different platforms. The 
use of mesothelial cysts as normal control tissues is unprecedented. Mesothelial cysts are 
relatively rare structures composed of normal pleural or peritoneal mesothelium which 
develop as liquid-filled translucent fibrous walls lined by a single layer of mesothelial 
cells(39). Therefore, mesothelial cysts may represent a valuable alternative to the use of 
immortalized cell lines or non-mesothelial tissues as a control. In the experimental system 
here used, we found that, with regard to mir-145 expression, all the sources of benign 
mesothelial tissue (cysts, pleural mesothelium, peritoneum) behaved similarly. Our initial 
screening has identified a number of microRNAs (n=19) whose levels of expression may 
segregate benign from malignant mesothelial tissues. Notably, some of the microRNAs 
identified in this study have been found by others and already shown to possess the power to 
discriminate between lung adenocarcinoma and mesothelioma tissues (mir-141, mir-200c, 
mir-193)(40). This represents an indirect biological validation of our findings. On the other 
hand, some other microRNAs (mir-145, mir-204, mir-486-5p, mir-1287) have not been 
described yet for mesothelioma, to the best of our knowledge. We have focused on mir-145 
for its potential to act pleiotropically as a tumor suppressor via targeting multiple relevant 
cancer genes (12, 41–48). We provide evidence here that hypermethylation of mir-145 
regulatory region is responsible for the low levels of this microRNA in both malignant 
mesothelial tissues and mesothelioma cell lines. We found that overexpression of mir-145 
by mimic compounds affected the levels of OCT4 and, indirectly, of its EMT-associated 
gene target, such as ZEB1. Both OCT4 and ZEB1 are intimately connected to the 
maintenance of stemness, epithelial to mesenchymal transition and cancer chemoresistance 
(18–20, 24). Mir-145 downregulation conveys clear protumorigenic advantages to 
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mesothelioma cells. Indeed, proliferation, clonal growth and migration of MPM cells are 
readily reduced by the transfection of “mimic” compounds and in vivo tumorigenicity is 
reduced as well. All this is unprecedented for MPM and shows how microRNA modulation 
is complex and how a change in the levels of a single microRNA may affect multiple 
pathways, impinging on key tumor features. EMT and chemoresistance are in fact major 
determinants of mesothelioma development and progression (26, 35). Mir-145 has multiple 
targets which are relevant to cancer progression. Although it is likely that multiple 
mechanisms underlie the anticancer effects of mir-145 re-expression in MPM cell lines, our 
observations suggest that OCT4 downregulation can be a main one. In fact, add-back of 
OCT4 into mimic-145 treated MPM cells at least partially restores the clonogenicity of the 
cells, while reducing significantly the number of senescent cells. These observations agree 
with the data from Beltran et al., showing that lentiviral expression of OCT4 in human 
mammary epithelial cells (HMECs) can “bypass” the spontaneous senescence occurring in 
those primary cultures after few passages(38). Conversely, the pro-senescence effects of 
mir-145 re-expression in MPM cells are reminiscent of the data from Bonifacio et al., (49) 
showing mir-145 upregulation in senescent human fibroblasts. Induction of chemoresistant 
cell populations is a side effect of pemetrexed and cisplatin treatment which limits their 
efficacy in vivo. This is fuelled by cytokines and growth factors secreted by senescent MPM 
cells in response to chemotherapy treatment, according to a Senescence Associated 
Secretory Phenotype (SASP) model(35, 50–52). The resulting chemoresistant cells are 
endowed with very high levels of EMT and stemness genes, including OCT4 and ZEB1(35). 
Indeed, we show here that pemetrexed treatment induces OCT4 and increases the number of 
OCT4 positive cells and the emergence of the latter cells may represent a mechanism of 
tumor progression(35). Mimic-145 treatment may, at least partially, counteract this 
phenomenon given its ability to downregulate OCT4 expression in pemetrexed treated 
samples.
One unanswered question of this study is whether mir-145 may act as a part of a larger 
group of microRNAs. In fact, we found that the distribution of the expression of mir-145 in 
our collected samples was strikingly similar to that of other 5 microRNAs (Fig.1A). 
Therefore, it is possible that all or some of the mentioned microRNAs may act as a 
functional cluster by targeting converging pathways. This is supported by the fact that at 
least some of the microRNAs identified in this study are known to target common EMT-
promoting factors (for example, mir-141 and 200c target ZEB1/2)(53–55). In this regard, it 
would be interesting in future work to investigate the relationship between mir-145 and the 
other microRNAs sharing a similar distribution, to unravel possible functional interactions. 
With regard to this, it is interesting that targeting of the ZEB1-EMT axis is a frequent 
predicted function of the mentioned microRNAs (56). This reflects the prominent role of 
these EMT players in MPM development(26, 27).
Materials and Methods
Sample collection
41 unmatched specimens (29 MPM and 12 mesothelial cysts) were collected from two 
different institutions in Italy (Regina Elena Cancer Institute, Rome and General Hospital S. 
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Vincenzo, Taormina). All the specimens were from formalin fixed and paraffin embedded 
tissues (FFPE) and initial diagnosis confirmed by expert histopatologists. 20 fresh biopsies 
(14 normal pleura vs 6 MPM) were obtained from Regina Elena Cancer Institute. An 
additional 36 snap-frozen samples (matched peritonea vs MPM) were used as a validation 
set of the results obtained with the initial screening and derived from the New York 
University Medical Center, New York, United States. The patients were not treated with any 
previous radio or radio-chemotherapy, before to undergoing surgery. Independent Ethical 
Committees from all the Institutions have approved the use of the samples.
RNA extraction, labeling and microarray hybridization
RNA from FFPE samples and cell lines was extracted using the miRneasy® FFPE kit 
(QIAGEN) and TRIZOL, respectively, following the manufacturer’s instructions. TRIZOL 
was used for the extraction of snap-frozen tissue specimens as well. Total RNA (200 ng) 
coming from tissues was labeled and hybridized to Human miRNA Microarray V2 Rel.16 
(Agilent). Scanning and image analysis were performed using the Agilent DNA Microarray 
Scanner (P/N G2565BA) equipped with extended dynamic range (XDR) software, according 
to the Agilent miRNA Microarray System with miRNA Complete Labeling and Hyb Kit 
Protocol manual. Feature Extraction Software (Version 10.5) was used for data extraction 
from raw microarray image files using the miRNA_105_Dec08 FE protocol. For the 
matched peritonea vs MPM samples, samples were extracted with TRIZOL and 5ug of Total 
RNA was processed as described elsewhere (57).
microRNA expression profiling and data analysis
Analysis of expression of 887 human microRNAs were performed using in house built 
routine by Matlab (The Mathworks Inc.). Signals were pre-processed with quantile 
normalization and log2 transformed. Samples with duplicates available were tested for 
quality control. Unpaired T-test and Wilcoxon test were used to identify differentially 
expressed features between mesothelioma samples and cysts. Deregulated miRNAs with 
pvalue less than 0,001 and FDR (False Discovery Rate) less than 0,05 were selected. 
Unsupervised hierarchical clustering and Principal Component Analysis were used to 
separate different subgroups of samples basing on the identified signature. Validation of the 
signature was obtained by RT-PCR.
Target Prediction
Diana mirPath (http://diana.cslab.ece.ntua.gr/pathways) using Targetscan 5 and Pictar was 
used for the in silico putative target prediction of the selected microRNAs.
Cell lines and culture conditions
Human cell lines HEK293, MSTO-211H, NCI-H2052 and NCI-H28 were obtained from 
ATCC (Rockville; MD, USA). HMC Human Primary Mesothelial cells were obtained from 
TEBU-BIO (France). All cell lines were cultured as monolayers at 37 C and 5% CO2 in 
DMEM/F12+GLUTAMAX (Invitrogen-GIBCO, Carlsbad, CA, USA) supplemented with 
10% fetal bovine serum (FBS) (Invitrogen-GIBCO), 5 ug/ml Insulin (SIGMA).
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Cell transfection
Pre-miRNA Precursor-Negative Control (Ambion) (Ctrl), Pre-miRNA145 (Ambion)
(mimic145) at final concentration of 5nM were transfected into the indicated MPM cell lines 
using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s instructions. 
OCT4 expression vectors were from Warren et al. (37), Addgene plasmid 26816. 
Lipofectamine 2000 (Invitrogen) was used to transfect the DNA vectors, according to the 
manufacturer’s instructions.
Luciferase target assay
HEK-293T cells were transiently co-transfected in 6-well dishes using Lipofectamine 2000 
(Invitrogen) with 2µg of OCT4-3’-UTR-(wt and mutant)-Luciferase vectors (a kind gift of 
Dr. Kenneth Kosik, UCSF Santa Barbara, CA, United States) 200 ng of the transfection 
control Renilla vector (phRLTK, Promega), and 500ng of mir-145 expression vector pEP-
mir-145 (Cell Biolabs, San Diego, CA USA). Cells were harvested 48 hours post 
transfection and luciferase activities were analyzed by the dual-luciferase reporter assay 
system (Promega, Madison, WI).
Reagents
Pemetrexed (Eli Lilly and Company, Indianapolis, IN, USA) and 5-aza-2′-deoxycytidine 
(Sigma, St Louis, MO) were dissolved according to the manufacturer’s instructions.
Cell viability assay
Manual counting and Trypan Blue dye exclusion assay were used to assess cell growth and 
viability were indicated.
5-Aza-2′-deoxycytidine treatment
Cells were plated in six-well plates on Day 0, and treated with a final concentration of 10 
µM 5aza-2′-deoxycytidine (Sigma, St Louis, MO) on alternative days beginning from Day 1, 
until Day 3. The treated cells were harvested on Day 4.
DNA isolation, sodium bisulfite conversion and pyrosequencing Analysis
Genomic DNA was isolated using the QIAamp DNA microKit (Qiagen, Hilden, Germany). 
Sodium bisulfite modification of 450 ng DNA was performed using the DNA Methylation 
kit (Diatech Pharmacogenetics) according to the manufacturer’s protocol. 5 out 12 
microliters of modified DNA was subjected to PCR amplification of the specific promoter 
region of pri-miR-145 using the Corbett Life Science Rotor-Gene™ 6000. The primer 
sequences are listed in Supplementary Table 1. The resultant PCR products were analyzed 
by gel electrophoresis to confirm the size of the product and rule out the formation of primer 
dimers. The specific PCR products were then subjected to quantitative pyrosequencing 
analysis using a PyroMark Q96 ID (Qiagen) according to the manufacturer’s protocol. The 
genomic location of the bisulfite pyrosequencing assays and the number of CpG sites 
investigated in each assay are shown in Figure 6. The pyrosequencing analysis was 
performed with PyroMarker CpG software 1.0.11 (Qiagen).
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In vitro migration assay
Wound healing assay. Cells seeded in 6-well tissue culture and grown to 95% confluence 
wounded with a sterile 10-µL pipet tip to remove cells by one perpendicular line. PBS1× 
washing was used to remove loosely attached cells. Digital micrographs were taken after 
scratching at the indicated times. Transwell migration assay. Migration assay was 
performed using a 24-well Boyden chamber with a non-coated 8-mm pore size filter in the 
insert chamber (Falcon). Cells (mimic 145- and control-transfected MSTO-211H) (5×104) 
were suspended in 0.5 ml DMEM/F12 media without containing FCS and seeded into the 
insert chamber. Cells were allowed to migrate for 48 h into the bottom chamber containing 
0,7 ml of DMEM/F12 media containing 5% FCS in a humidified incubator at 37°C in 5% 
CO2. Migrated cells which had attached to the outside of the filter were visualized by 
staining with DAPI and counted.
Clonogenic assays
MPM cell lines were grown to 70% confluence and pulse treated with the indicated drugs or 
transfected as indicated. 16hrs later, cells were detached and seeded at 500–1500 cells/well 
into 6-well dishes (COSTAR) in drug-free media. Fresh media (25%) was added every three 
days. Colonies were stained with crystal violet and colonies (>50 cells) counted after 10– 14 
days.
cDNA synthesis and Q-PCR
Total RNA was extracted using the TRIZOL Reagents (GIBCO). Real time-PCR of miRNA 
expression was performed using TaqMan MiRNA® Assays (Applied Biosystems, Foster 
City, CA, USA) according to the manufacturer's protocol. RNU6B and RNU49 were used as 
endogenous controls to standardize miRNA expression. For measurement of the precursor 
miRNA expression, PCR was perfomed using 2× red Mix DNA Polymerase MasterMix 
(RBC Bioscence) using the primers published by Zhang et al.49. PCR was performed at 
95°C for 5 min, 32 cycles at 95°C for 30 s, 60°C for 40 s and 72°C for 40 s followed by a 
final extension at 72°C for 10 min. The PCR products were loaded on 2 % agarose gel for 
analysis.
Lysate preparation and immunoblotting analyses
Cells were lysed in buffer with 50 mM Tris-HCl pH 8, with 1% NP-40 (Igepal AC-630) 
150mM NaCl, 5mM EDTA. Extracts were centrifuged at 14000 ×rpm for 15min to remove 
cell debris. Protein concentrations were determined by colorimetric assay (Bio-Rad). 
Western blotting was performed using the following primary antibodies: mouse monoclonal 
anti-GAPDH (Sigma Aldrich A228), TUBULIN (Sigma Aldrich T6074), OCT4 C-10 (Santa 
Cruz Biotechnology, inc. sc-5279, OCT4A (C30A3) Rabbit mAb Cell Signaling #2840), 
ZEB1 (Cell Signaling D80D3), p21 (Cell Signaling 12D1), laminB1 (ABCAM 16048), 
histone H3 Acetyl K9 (ABCAM 61231), Histone H3 (ABCAM 10799). Secondary 
antibodies used were goat anti-mouse, conjugated to horseradish peroxidase (Amersham 
Biosciences, Piscataway, NJ, USA). Immunostained bands were detected by 
chemiluminescent method (Pierce Rockford, IL, USA).
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SA-β-gal staining
SA-β-galactosidase staining was performed on adherent cells according to manufacturer’s 
instructions (Cell Signaling, Danvers, MA, USA).
Immunofluorescence microscopy
Cells (5×103 cells per chamber) were seeded into 8-chambers culture slides (BD Falcon, 
Franklin Lakes, NJ). The next day, cells were rinsed with ice-cold PBS and fixed with 4% 
paraformaldehyde for 10 min at room temperature followed by permeabilization with 0,1% 
Triton X-100. The cells were subjected to immunofluorescence staining with Oct-3/4 
Prediluted Monoclonal Antibody (PM 313 AA, BIOCARE Medical, Concord, CA 94520 
USA) for 2 h at room temperature. The cells were then washed with cold PBS three times 
for 3 min each, and counterstained with DAPI (4',6-Diamidino-2-Phenylindole, 
Dihydrochloride). Fluorescent staining of Senescence Associated Heterochromatin Foci 
(SAHF). To visualize SAHF, DAPI was used to stain for DNA after fixation and 
permeabilization of the cells. The cells were examined by fluorescence microscopy (Zeiss 
Axiophot). Fluorescence intensities from images of six randomly selected microscopic fields 
of cells were semi-quantitatively analyzed by densitometry (ImageJ software, NIH Image). 
The Corrected Total Cell Fluorescence (CTCF) was calculated by the formula: CTCF = 
Integrated Density – (Area of selected cell * Mean fluorescence of background readings).
Immunohistochemistry
OCT4 was analyzed by immunohistochemistry using the anti-OCT4 (Santa Cruz 
Biotecnology, inc. sc-5279) in a series of 10 mesothelioma patients subjected to surgery at 
the Regina Elena Cancer Institute (Rome, Italy) between 2005 and 2008. Formalin-fixed, 
paraffin-embedded 5µm sections were stained with Haematoxylin and Eosin or stained with 
anti-Oct-4 antibody (SC5279 LOTTJ1612, Santa Cruz, 1:50, BENCHMARK ULTRA 
VENTANA, Roche, Tucson, USA). Seven randomly chosen fields from each sample were 
scored.
Flow Cytometry
Cells were detached by PBS/EDTA 2mM and resuspended for ab staining at 1×106 cells/
100uL in PBS/BSA1%. The following antibodies were used: anti-OCT4 rabbit monoclonal 
(INVITROGEN), IgG2a isotype matched negative control (Invitrogen), AlexaFluor-488 
conjugated anti rabbit antibody. Data were acquired using a FACS Calibur instrument and 
analysis was performed by using FlowingSoftware 2.0 (Cell Imaging Core, University of 
Turku, Finland).
Xenograft transplantation
Suspensions of 3 × 106 MSTO-211H cells were injected subcutaneously in PBS 1×/Matrigel 
(BD Biosciences) into 5-week old male SCID mice (Charles River, Milan). Body weight and 
clinical signs of the mice were determined every 3 d. Tumor volume was calculated by using 
the formula: V = π/6 × length × width (by manual caliper). All tumorigenicity assays were 
performed according to the guidelines set by the internal Ethical Committee.
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Statistical analysis
Data were analyzed using Student’s t test with correction for data sets with unequal 
variances. EXCEL software was used to graph and calculate linear regression of the fig. 4E.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. MicroRNA expression profile of MPM specimens
A. Heat map. Levels (Log2) of 19 differentially expressed microRNAs among malignant 
and benign mesothelium (cysts). B. PCA plot showing the distribution of the training set of 
samples according to the levels of the 19 mirs as from A. C. Mir-145 expression in benign 
vs malignant mesothelial tissues. Box plot: Quantitative PCR. Average levels of mir-145 
from an independent validation set of samples. RNA collected from fresh biopsies of 
unmatched mesothelioma (left n=6) and benign pleural tissue (right, n=14) samples, 
respectively. The “+” indicates an outlier. D. Levels of mir-145 in matched peritoneal vs 
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MPM sample tissues. Box plot: Average levels of mir-145 (intensity values-Log2) from an 
independent set of samples. RNA collected from fresh biopsies of matched mesothelioma 
and peritoneal tissue (n=36). The “+” indicate outliers. E. Expression of mir-145 in the 
indicated cell lines. Q-PCR. Levels of mir-145 in untransformed mesothelial cells (HMC) 
vs MPM cell lines (Log2). Histogram bars represent mean ± standard deviation of at least 
three independent replicates. p-values are reported in the lower left side.
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Figure 2. Re-expression of mir-145 affects protumorigenic properties of the MPM cell lines
A. Left panels: Proliferation of ctrl and mimic-145 transfected MPM cells as assessed by 
Trypan blue staining. The percentage of live cells (control cells/mimic-145 expressing cells-
Y-axis) at the indicated times (xaxis) is reported.. Middle and right panels: Clonogenic 
assay: representative micrographs of colonies formed by control (ctrl) and mimic-145 
transfected MPM cell lines. Histogram bars represent mean ± standard deviation of at least 
three independent replicates. B Left panel: representative micrographs of transwell 
migration assays of MSTO-211H cells transfected with ctrl- or mimic-145. DAPI staining 
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was used to quantify the migrated cells on the outer surface of the filter. Scale bar: 100µm. 
Right panel: histogram shows the percentage of migrated cells at the indicated times. Bars 
represent mean ± standard deviation of at least two independent replicates. The p-value 
refers to matched control vs mimic-145 transfected samples. C. mir-145 has anticancer 
effects in vivo. Briefly, SCID mice were subcutaneously transplantated with MSTO-211H 
cells (3 × 106 cells/mouse) transfected with either ctrl- or mimic-145 16hrs before injection. 
No differences in cell viability were observed between the two groups of injected cells at 
time of injection. C. Graph showing the average tumor volumes measured at day 47 p.i. 
Horizontal bars represent the average tumor volume of the measurable masses. Dotted line 
separates engrafted tumors (volume >150mm3 at termination) from non-neoplastic tissue or 
regressed tumors (volume >150mm3 at termination).
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Fig. 3. mir-145 induces senescence in MPM cell lines
A. Upper panel. Representative micrographs of SA-β-gal staining of MSTO-211H cells 
transfected with control or mimic-145. Scale bar: 100µm. Lower panel. Histogram showing 
the percentage of SA-β-gal positive cells in ctrl or mimic-145 transfected MSTO-211H and 
NCI-H2052cells. Histogram bars represent mean ± standard deviation of at least three 
independent replicates.. B. Western Blot analysis of whole cell lysates obtained from ctrl- 
and mimic-145-transfected NCI-H2052 cells stained with anti-Lamin B1, anti-histoneH3, 
anti-acetyl-histoneH3(K9), anti-p21 or anti-actin antibodies (the latter as a loading control). 
C. Senescence Associated Heterochromatin Foci (SAHF) formation occurs in 
mimic-145 transfected cells. Histogram showing the percentage of SAHF positive nuclei in 
ctrl- and mimic-145 treated MSTO-211H and NCI-H2052 cells, respectively. Bars represent 
mean ± standard deviation of at least two independent replicates. The p-value refers to 
matched control vs mimic-145 transfected samples.
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Figure 4. Mir-145 targets OCT4 in MPM cell lines A. Upper panel
Schematic representation of the mir-145 target sequence within the OCT4 3’UTR (+138 to 
+157bp). Lower panel. Transfection of HEK293 cells with mimic-145 inhibited the 
translation of a luciferase-expressing plasmid containing a wt-3’UTR from OCT4 and not 
that of a its 3’UTR deleted counterpart. Histogram bars represent mean ± standard deviation 
of at least two independent replicates Statistics: NS, not significant. B. Representative 
western blotting analysis of whole cell lysates from control and mimic-145 transfected cells, 
either mock-transfected (left panels) or transfected with an OCT4 expression vector 
Cioce et al. Page 23
Oncogene. Author manuscript; available in PMC 2015 December 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
(retaining the wt 3’UTR region of the gene) (right panels) and stained with anti-OCT-4 
antibodies or anti-GAPDH as a loading control. C Left panel: indirect immunofluorescence 
staining of MSTO-211H cells transfected with GFP (green, arrows) and cotransfected with 
either control or mimic-145, fixed and stained with OCT4 antibody (red). Nuclei were 
revealed by DAPI staining (blue). Scale bar: 10µm. Right panel: Semi-quantitative 
evaluation of the results from MSTO-211H and NCI-H2052 cells transfected as in left panel. 
Histogram bars represent mean ± standard deviation of at least two independent replicates. 
The p-value refers to matched control vs mimic-145 transfected samples. D. Upper panel. 
FACS plot. MSTO-211H cells transfected with control (left) or mimic-145 (right) stained 
with OCT4 antibodies. Percentage of OCT4 positive cells (gate:red) was calculated after 
subtracting the background (cells stained with isotype matched antibody). Lower panel. 
Histogram bars represent mean ± standard deviation of at least two independent replicates of 
MSTO-211H and NCI-H2052 cells treated as from upper panel. The p-value refers to 
matched control vs mimic-145 transfected samples. E. The levels of mir-145 and OCT4 
inversely correlate in vivo. Upper panel. Representative images of paraffin-embedded 
sections of mesothelioma (”MM”) or benign mesothelial tissue (“cyst”) stained with 
Haematoxylin-Eosin (left) or with OCT4 antibody (right). Scale bar, 100µm. Quantitative 
evaluation of mir-145 levels (x-axis: Log2 expression intensity) and number of OCT4 
positive cells (y-axis: percentage) in mesothelioma (black circles) vs benign mesothelial 
tissues (white circles). Straight line: predicted values. r value from a linear regression model 
is reported in the text.
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Figure 5. Antagonistic effects of mir-145 and OCT4 on the tumorigenicity of MPM cells
A. mimic-145 transfection counteracts the OCT4 increase in pemetrexed-treated MPM cells. 
FACS staining of MSTO-211H cells transfected with control (left) or mimic-145 (right) 
(24hrs), treated with pemetrexed (72 hrs) and stained with OCT4 antibodies. Percentage of 
OCT4 positive cells (gate:red) was calculated after subtracting the background (cells stained 
with isotype matched antibody). Reported values represent the mean ± standard deviation of 
at least two independent replicates.. B. Representative western blot analysis of whole cell 
lysates from vehicle or pemetrexed-treated control- and mimic-145 transfected cells, either 
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and stained with anti-OCT-4 antibodies or anti-ACTIN as a loading control. C. 
Overexpression of OCT4 rescues the effects of mimic-145. Left panel. Clonogenic assay. 
Representative micrograph of MSTO-211H cells transfected with either ctrl or mimic-145 
and subsequently transfected with empty vector (EV) or OCT4 expression vector (retaining 
the wt 3’UTR sequence).Cells were stained with Crystal Violet 7 days later. Right panel. 
Quantitative analysis of clonogenic assays. Histogram bars represent mean ± standard 
deviation of at least three independent replicates. Statistics: NS, not significant. D. Left 
panel. SA-β-gal staining of MSTO-211H transfected with empty (EV) or OCT4-expressing 
vectors and subsequently (16hrs later) transfected with ctrl- or mimic-145. Scale bar: 20µm 
Right panel. Histograms showing the percentage of SA-β-gal positive cells as from left 
panel. Histogram bars represent mean ± standard deviation of at least three independent 
replicates.
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Figure 6. DNA methylation affects the levels of mir-145 in MPM samples
A. Schematic representation of the miR-145 promoter regions containing the CpG islands 
analyzed in 6B. B. Representative results of pyrosequencing assays from normal 
mesothelium (upper panel) and malignant mesothelium (lower panel). C. Histogram 
showing the average levels of methylation of the mir-145 regulatory regions in normal 
mesothelial tissues (n=5) and mesothelioma samples (n=3). Histogram bars represent mean 
± standard deviation of at least two independent replicates.
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TABLE 1
Features of the MPM specimens analyzed in Fig.1A.
Histotype n %
Epithelioid 25 86.2
Biphasic 3 10.3
Desmoplastic 1 3.5
T status
T2 9 31
T3 11 37.9
T4 5 17.3
unknown 4 13.8
Node status
N0 14 48.3
N1–3 10 34.5
unknown 5 17.2
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